PL2736491T3 - Kompozycje bepotastyny - Google Patents

Kompozycje bepotastyny

Info

Publication number
PL2736491T3
PL2736491T3 PL12732455T PL12732455T PL2736491T3 PL 2736491 T3 PL2736491 T3 PL 2736491T3 PL 12732455 T PL12732455 T PL 12732455T PL 12732455 T PL12732455 T PL 12732455T PL 2736491 T3 PL2736491 T3 PL 2736491T3
Authority
PL
Poland
Prior art keywords
bepotastine
compositions
bepotastine compositions
Prior art date
Application number
PL12732455T
Other languages
English (en)
Inventor
Angel Padilla
George Baklayan
Original Assignee
Bausch & Lomb Incorporated
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb Incorporated, Mitsubishi Tanabe Pharma Corporation filed Critical Bausch & Lomb Incorporated
Publication of PL2736491T3 publication Critical patent/PL2736491T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL12732455T 2011-01-04 2012-01-03 Kompozycje bepotastyny PL2736491T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161429721P 2011-01-04 2011-01-04

Publications (1)

Publication Number Publication Date
PL2736491T3 true PL2736491T3 (pl) 2017-09-29

Family

ID=46457931

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12732455T PL2736491T3 (pl) 2011-01-04 2012-01-03 Kompozycje bepotastyny

Country Status (12)

Country Link
US (2) US20120323178A1 (pl)
EP (1) EP2736491B1 (pl)
JP (1) JP5683719B2 (pl)
KR (1) KR101546596B1 (pl)
CN (1) CN103269687B (pl)
AU (1) AU2012204557B2 (pl)
BR (1) BR112013017183A2 (pl)
CA (1) CA2822683C (pl)
ES (1) ES2626134T3 (pl)
MX (1) MX337775B (pl)
PL (1) PL2736491T3 (pl)
WO (1) WO2012094283A2 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551752T3 (es) * 2010-10-06 2015-11-23 Bausch & Lomb Incorporated Composiciones de bepotastina
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2847207B1 (en) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Fluticasone propionate nanocrystals
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
ES2920802T3 (es) * 2013-03-26 2022-08-09 Optinose As Administración nasal
MX367674B (es) 2013-09-13 2019-08-30 Glenmark Specialty Sa Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina.
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
CN105792828A (zh) 2013-10-04 2016-07-20 格兰马克药品有限公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN103816121B (zh) * 2014-03-07 2016-01-20 上海现代药物制剂工程研究中心有限公司 苯磺酸贝他斯汀鼻腔喷雾剂及其制备方法
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
JP6945614B2 (ja) * 2014-03-26 2021-10-06 オプティノーズ アズ 経鼻投与
WO2015183047A1 (ko) * 2014-05-30 2015-12-03 동아에스티 주식회사 베포타스틴과 글리세릴베헤네이트를 포함하는 약제학적 제제
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
US9980975B2 (en) * 2015-01-22 2018-05-29 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
US9119876B1 (en) 2015-03-13 2015-09-01 Par Pharmaceutical, Inc. Epinephrine formulations
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
JP7106852B2 (ja) * 2016-12-20 2022-07-27 大正製薬株式会社 懸濁型外用液剤
WO2019046844A1 (en) * 2017-09-02 2019-03-07 Iview Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS FORMING IN SITU A GEL AND THEIR USES FOR SINUS DISEASES
HUE071622T2 (hu) * 2018-02-23 2025-09-28 Glenmark Specialty Sa Allergiás Rhinitis kezelése gyermekgyógyászati alanyoknál mometazon és olopatadin kombinációjával
WO2019183416A1 (en) 2018-03-23 2019-09-26 Nevakar Inc. Epinephrine compositions and containers
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CA3100679A1 (en) 2018-06-08 2019-12-12 Toko Yakuhin Kogyo Co., Ltd. Fluticasone furoate nasal preparation composition
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
US20210283074A1 (en) * 2020-03-16 2021-09-16 Nasus Pharma Ltd. Polymeric Compositions for Intranasal Administration
IL301496A (en) * 2020-09-24 2023-05-01 Nflection Therapeutics Inc Treatment of cognitive dysfunction with pyrrolopyridine-aniline compounds
CN117954002B (zh) * 2024-01-05 2024-10-22 苏州腾迈医药科技有限公司 分子对关系的展示方法及装置、介质

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8902300D0 (en) 1989-02-02 1989-03-22 Bryce Smith Derek Antirhinoviral preparations
CN1222852A (zh) * 1996-06-04 1999-07-14 普罗克特和甘保尔公司 含鼻内类固醇和抗组胺剂的鼻喷雾剂
AU3153797A (en) * 1996-06-04 1998-01-05 Procter & Gamble Company, The A nasal spray containing an intranasal steroid and an antihistamine
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
TW486475B (en) 1996-12-26 2002-05-11 Ube Industries Acid addition salt of optically active piperidine compound and process for preparing the same
GB9918559D0 (en) * 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
PL367337A1 (pl) * 2001-05-31 2005-02-21 Pharmacia Corporation Przenikająca przez skórę kompozycja selektywnego inhibitora cyklooksygenazy-2
KR20050044550A (ko) * 2001-12-05 2005-05-12 알콘, 인코퍼레이티드 비염 치료를 위한 η1 길항제 및 안전한 스테로이드제의용도
AU2003264859A1 (en) * 2001-12-21 2003-12-19 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
AU2003252746A1 (en) * 2002-07-31 2004-02-16 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
CA2495830C (en) * 2002-08-30 2012-08-21 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
EP1675550A4 (en) * 2003-09-24 2007-10-10 Combinatorx Inc THERAPEUTIC DOSAGE DIAGRAMS FOR ADMINISTRATION OF MEDICINAL COMBINATIONS
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
WO2005030793A2 (en) * 2003-09-24 2005-04-07 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
JP5607291B2 (ja) * 2004-11-24 2014-10-15 メダ ファーマシューティカルズ インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
PL1919450T3 (pl) * 2005-09-01 2014-11-28 Meda Ab Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
WO2008047149A1 (en) * 2006-10-19 2008-04-24 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
KR100878698B1 (ko) * 2007-04-05 2009-01-13 한미약품 주식회사 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물
KR20100014565A (ko) 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 tnfa의 억제제 및 항히스타민의 용도
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
KR20090061972A (ko) 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 p-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
US20110200646A1 (en) * 2008-09-02 2011-08-18 Charanjit Bountra The TRPVL Antagonists SB-795498 For Treating Rhinitis
JP2010195716A (ja) 2009-02-25 2010-09-09 Takeda Chem Ind Ltd 点鼻睡眠導入剤
ES2551752T3 (es) * 2010-10-06 2015-11-23 Bausch & Lomb Incorporated Composiciones de bepotastina

Also Published As

Publication number Publication date
JP5683719B2 (ja) 2015-03-11
WO2012094283A3 (en) 2012-10-26
BR112013017183A2 (pt) 2017-07-25
AU2012204557A1 (en) 2013-05-02
US20120255544A1 (en) 2012-10-11
KR20130135296A (ko) 2013-12-10
CA2822683C (en) 2015-05-12
WO2012094283A2 (en) 2012-07-12
EP2736491A4 (en) 2014-07-09
ES2626134T3 (es) 2017-07-24
CA2822683A1 (en) 2012-07-12
US20120323178A1 (en) 2012-12-20
EP2736491B1 (en) 2017-04-05
CN103269687B (zh) 2016-09-14
JP2014501779A (ja) 2014-01-23
EP2736491A2 (en) 2014-06-04
CN103269687A (zh) 2013-08-28
KR101546596B1 (ko) 2015-08-21
US10736841B2 (en) 2020-08-11
AU2012204557B2 (en) 2015-05-14
MX2013007409A (es) 2013-11-01
MX337775B (es) 2016-03-18

Similar Documents

Publication Publication Date Title
PL2736491T3 (pl) Kompozycje bepotastyny
ZA201404448B (en) Peracid-generating compositions
GB201113662D0 (en) Pharmaceutical compositions
AP3656A (en) Pharmaceutical compositions
ZA201308208B (en) Pharmaceutical compositions
GB201117619D0 (en) Compositions
SG11201401335QA (en) Compositions
GB201117621D0 (en) Compositions
PL2624836T3 (pl) Kompozycje bepotastyny
GB2496447B (en) Compositions
GB201110833D0 (en) Compositions
LT2734186T (lt) Kompozicija
GB201118181D0 (en) Pharmaceutical compositions
GB201121258D0 (en) Composition
GB201103942D0 (en) Compositions
GB201103964D0 (en) Composition
GB201110132D0 (en) compositions
GB201104849D0 (en) Compositions
EP2711011A4 (en) COMPOSITION CONTAINING PANAXADIOL
LT2726579T (lt) Kompozicija
GB201122213D0 (en) Compositions
GB201109121D0 (en) Compositions
GB201122214D0 (en) Compositions
GB201103943D0 (en) Compositions
GB201121028D0 (en) Compositions